News
Join our newsletter
Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.
EpiVax Enters its Next Chapter with SV Health Investors
EpiVax Enters its Next Chapter with SV Health...
Advancing Immunogenicity Science: EpiVax in 2025
In 2025, EpiVax advanced the science of...
EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide
EpiVax and FDA Scientists Publish New Insights...
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
EpiVax Appoints Dr. Vibha Jawa to Lead...
The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies
The Role of Treg Epitopes (Tregitopes) in...
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements
EpiVax Strengthens Technology Leadership Amid...
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
PROVIDENCE, R.I., Dec. 6, 2024...
Supporting Health Equity: EpiVax Highlights Partnerships and New Research from Clínica Esperanza and GAIA Vaccine Foundation
PROVIDENCE, R.I., Dec. 6, 2024...
EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs
PROVIDENCE, R.I., Oct. 24,...
Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development
PROVIDENCE, RI, April 1, 2024 /PRNewswire/ --...
EpiVax Posters at AAPS NBC 2024
If you missed the posters that we presented at AAPS NBC 2024, don’t worry!
Eisai Licenses ISPRI Toolkit
Eisai Licenses EpiVax's ISPRI Toolkit for...